SciSparc (SPRC)announced that its collaboration with Clearmind Medicine (CMND) has led to the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders. The patent application covers the use of 3-Methylmethcathinone in combination with SciSparc’s Palmitoylethanolamide. This innovative combination aims to address the complex neurobiological and psychological factors associated with eating disorders, offering a potential new avenue for treatment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRC:
- SciSparc Extends Deadline for Miza III Ventures Deal
- SciSparc Ltd. Extends Merger Agreement with AutoMax Motors
- SciSparc files to sell 61.21M ordinary shares for holders
- Biotech Alert: Searches spiking for these stocks today
- SciSparc and Clearmind Advance Cocaine Addiction Treatment with South Korean Patent Application